



200.1079CON2

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Serial No.: 10/056,347
Applicant: Ronald M. Burch, et al.
Filed: January 25, 2002
Art Unit: 1639
Examiner: Bennett M. Celsa
For: **Analgesic Combination of Oxycodone and Meloxicam**

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

November 9, 2004

INFORMATION DISCLOSURE STATEMENT

Sir:

In accordance with Applicant's duty of disclosure under 37 C.F.R. §1.56 and the provisions of 37 C.F.R. §§ 1.97 and 1.98, Applicants hereby make of record the single document listed on the accompanying Form PTO-1449 for consideration by the Examiner in connection with the examination of the above-identified patent application.

The document reports the assessment of the effects of combined administration of oxycodone with either of celecoxib, etodolac or rofecoxib, as performed by Purdue Pharma L.P., which is associated with the assignee of the present invention.

This Information Disclosure Statement is being filed after a First Office Action but before a Final Office Action or Notice of Allowance. Pursuant to 37 C.F.R. § 1.98(c), a check for \$180.00 is enclosed to cover the required fee. However, if it is determined that any fee is due, the Examiner is authorized to charge said fee to Attorney Deposit Account No. 50-0552.

11/15/2004 RMEBRANT 00000013 10056347

01 FC:1806


180.00 DP

It is respectfully requested that the reference cited on the accompanying Form PTO-1449 be considered and made of record.

Respectfully submitted,


DAVIDSON, DAVIDSON & KAPPEL, LLC

By: _____


Robert J Paradiso
Reg. No. 41,240

DAVIDSON, DAVIDSON & KAPPEL, LLC
Patents, Trademarks and Copyrights
485 Seventh Avenue, 14th Floor
New York, New York 10018
(212) 736-1940

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: 200.1079CON2		SERIAL NO.: 10/056,347	
LIST OF PRIOR ART CITED BY APPLICANT (Use several sheets if necessary)				APPLICANT(S): Ronald BURCH et al.			
				FILING DATE: January 25, 2002		GROUP: 1639	



U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA						
	AB						
	AC						

FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
						<div style="display: flex; justify-content: space-between; padding: 0 5px;"> Yes No </div>	
	AD						

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)	
AE	Purdue Discovery Research, Department of Neuropharmacology Study Report "Assessment of the Effects of Combined Administration of Oxycodone and Cox II inhibitors, Celecoxib, Etodolac and Rofecoxib, in the Rat FCA Model of Inflammatory Pain"; July 28, 2003
AF	
AG	
AH	
AI	
AJ	
AK	
AL	
AM	
AN	
AO	
AP	
AQ	
AR	
AS	

EXAMINER		DATE CONSIDERED
----------	--	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

UNITED STATES PATENT AND TRADEMARK OFFICE

Re: Application of: Ronald M. BURCH, et al.
Serial No.: 10/056,347
Filed: January 25, 2002
Examiner: Celsa, Bennett M
For: **ANALGESIC COMBINATION OF
OXYCODONE AND MELOXICAM**

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA, 22313-1450

November 9, 2004

Sir:

In accordance with Applicant's duty of disclosure under 37 C.F.R. §1.56 and the provisions of 37 C.F.R. §§ 1.97 and 1.98, Applicants hereby make of record the references listed on the accompanying Form PTO-1449 (1 page) for consideration by the Examiner in connection with the examination of the above-identified patent application.

In accordance with 37 C.F.R. § 1.98 (d), copies of the cited references AJ to AL are not enclosed as these references were cited by the Examiner in the parent case, U.S. Application No. 09/154,354. However, in accordance with 37 C.F.R. § 1.98 (a), copies of listed references AM to AT are enclosed.


The present Information Disclosure Statement is filed under 37 C.F.R. §1.97(b), after the mailing of a first Office Action on the merits. Accordingly, a fee of \$ 180.00 is enclosed. However, if it is determined that there is a deficiency or an overpayment, the Examiner is authorized to charge said deficiency or credit said overpayment to Attorney Deposit Account No. 50-0552.

It is respectfully requested that the reference cited on the accompanying Form PTO-1449
be considered and made of record.

Respectfully submitted,

DAVIDSON, DAVIDSON & KAPPEL, LLC

By

A handwritten signature in dark ink, appearing to read "R. J. Paradiso", written over a horizontal line.

Robert J. Paradiso
Reg. No. 41,240

Davidson, Davidson & Kappel, LLC
485 Seventh Avenue, 14th Floor
New York, New York 10018
(212) 736-1940

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: 200.1079CON2		SERIAL NO.: 10/056,347	
LIST OF PRIOR ART CITED BY APPLICANT				APPLICANT(S): Ronald BURCH et al.			
(Use several sheets if necessary)							
				FILING DATE: January 25, 2002		GROUP: 1639	
U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
							YES NO
	AH						
	AI						
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)							
	AJ	The Merck Index, 12 th edition, Merck & Co. Publishers, p.1194 (1996)					
	AK	Goodman and Gillman's The Pharmacological Basis of Therapeutics, 6 th edition, Macmillan Publishing Co., "Chapter 22: Opioid Analgesics and Antagonists," p.494-497, esp. Tables 22-1, p. 496 (1980)					
	AL	Rorarius et al., "Non-steroidal Anti-inflammatory Drugs for Postoperative Pain Relief," Current Opinion in Anesthesiology, 7:358-362 (1994)					
	AM	Friedel et al., "Nabumetone- A Reappraisal of its Pharmacology and Therapeutics Use in Rheumatic Diseases," Drugs Vol. 45 (1):131-156, (1993)					
	AN	Eversmeyer et al., "Safety Experience With Nabumetone Versus Diclofenac, Naproxen, Ibuprofen, and Piroxicam in Osteoarthritis and Rheumatoid Arthritis, The American Journal of Medicine, Vol. 95 (Suppl. 2A) pp. 10S-18S					
	AO	Lipani, "Clinical Update of the Relative Safety of Nabumetone in Long-Term Clinical Trials," Inflammopharmacology (1995) Vol 3(4) pp. 351-361					
	AP	Tanaka et al., "Pharmacological Studies of the New Antiinflammatory Agent 3-Formylamino-7-methylsulfonylamino-6-phenoxy-4H-1-benzopyran-4-one," Arzneim-Forsch./Drug res. 42 (II), Nr. 7, pp. 935-944 (1992)					
	AQ	Swingle et al., "Preclinical Pharmacological Studies With Nimesulide," Drugs Exptl. Clin. Res. Vol. X (8-9) pp. 587-597					
	AR	Rabasseda, "Nimesulide: A Selective Cyclooxygenase 2 inhibitor Antiinflammatory Drug," Drugs of Today Vol 32, No.5 (1996), p9. 365-384					
	AS	Siebert et al., "Pharmacological and Biochemical Demonstration of the Role of Cyclooxygenase 2 in Inflammation and Pain," PNAS USA Vol.91 (Dec. 1994) pages 12013-12-17					
	AT	Richardson et al., "The Clinical Implications of Inhibition of the Inducible Form of Cyclo-oxygenase," Drug Safety Vol. 15(4), pp. 249-260 (Oct. 1996)					
EXAMINER				DATE CONSIDERED			
<p>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>							